Hasan Jafri of MedImmune and COMBACTE Magnet: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Hasan Jafri has been involved in the design and conduct of multiple Phase 1‐4 clinical studies to assess novel small and large molecules against bacterial, viral and fungal pathogens. Prior to joining MedImmune, Dr. Jafri served as a professor in pediatric infectious diseases and clinical science research at the University of Texas Southwestern Medical Center at Dallas. He was …

Ribhi Shawar of FDA: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Ribhi Shawar currently serves as the Branch Chief at the Division of Microbiology in the Office of In vitro Diagnostic and Radiological Health (OIR) at the Center for Devices and Radiological Health (CDRH) at FDA where he specializes in the area of antimicrobial susceptibility testing and detection of resistance. Dr. Shawar has a Ph.D. in Medical Microbiology and an M.Sc. in …

Jens Eckstein of SR One: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Eckstein, President, comes to SR One from TVM Capital where he was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVMs Boston life sciences practice where he focused on earlier-stage investments. He is currently a Director of Thrasos Therapeutics, Palleon Pharma, Decibel Therapeutics, Gladius Pharmaceuticals and …

Anders Karlén of Uppsala University: Featured Speaker at World Anti-Microbial Resistance Congress

Anders Karlén, Professor in Computer-aided drug design, Uppsala University, Sweden, is presently the overall medicinal chemistry project leader for drug discovery efforts currently directed at five different anti-bacterial targets at Uppsala University. Several of these projects have been run within EU framework 6 and 7 programmes. Since February 2014 he is the Leader of the Managing Entity and co-coordinator of the …

Jane Knisely of NIH-NIAID: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Jane Knisely is a Program Officer in the Bacteriology and Mycology Branch of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease, NIH, where she oversees scientific programs related to antimicrobial resistance and antibacterial drug development. Specifically, Jane is the program officer for NIAID’s Antibacterial Resistance Leadership Group, a clinical trials group focused …

Evolving existing drug classes to meet the challenges of unmet medical needs: navigating regulatory perspectives

“Evolving existing drug classes to meet the challenge of unmet medical needs: navigating regulatory perspectives “

Mark Jones, PhD, Head of Project Management at Basilea Pharmaceutica joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘navigating regulatory perspectives ‘. In this presentation, learn about navigating regulatory perspectives in the context of the unmet medical need for new antifungals . Download the presentation to understand more about: Where will our new antifungals come from? The …

Crestone: Novel Drug Discovery Programs for Infectious Diseases

“Crestone: Novel Drug Discovery Programs For Emerging Infectious Diseases”

Thale Jarvis of Crestone joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘novel drug discovery programs for emerging infectious diseases’. In this presentation, learn about CRS3123 for the treatment of Clostridium difficile infections. Download the presentation to understand more about: Crestone’s mission Clostridium difficile infection (CDI) CRS3123: Key advantages vs. competition …and much more! Get your copy …

Chris Houchens of BARDA: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Christopher Houchens, PhD joined the US Government’s Biomedical Advanced Research and Development Authority (BARDA) in April 2012. In his previous role as a BARDA Project Officer, Chris lead multiple interdisciplinary product development teams responsible for advancing the development, manufacture, clinical and non-clinical evaluation, and regulatory approval of novel drugs against multidrug resistant organisms, emerging infectious diseases and biothreat agents. In …

CARB-X: The largest public-private partnership in the world is all about AMR

The largest public-private partnership in the world has been formed, and its purpose is progress in the fight against antimicrobial resistance. As discussed in a Contagion article, ‘World’s Largest Partnership Formed to Fight Antimicrobial Resistance‘, the US Department of Health and Human Services issued a press release announcing CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a union of the Wellcome …

CARB-O Loading: BARDA's Efforts to Revitalize the Antibiotic Pipeline

“CARB-O Loading: BARDA’s Efforts to Revitalize the Antibiotic Pipeline”

Melissa Stundick, PhD, Chief of Anti-Infectives Branch of the US Department of Health and Human Services joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘BARDA’s efforts to revitalize the antibiotic pipeline’ . In this presentation, learn about why BARDA is funding antibacterial development, as well as BARDA’S vision for 2016 and beyond . Download this presentation to …